Polycythemia Vera · line 2 · Anagrelide — ET 2L cytoreduction (HU-intolerant / HU-resistant)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-ANAGRELIDE-ET |
| ID | IND-PV-ANAGRELIDE-CONTINUOUS |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-PV |
| Sources | SRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 SRC-PT1-HARRISON-2005 |
Notes
STUB — pending Clinical Co-Lead sign-off. line_of_therapy: 2 reflects post-HU failure salvage. Concurrent ASA + phlebotomy continuation expected. Engine activates after HU intolerance/resistance documented per ELN criteria. Reference REG-ANAGRELIDE-ET (originally authored for ET) used as proxy; PV-specific REG- not authored.
Used By
No reverse references found in the YAML corpus.